SEARCH

SEARCH BY CITATION

References

  • 1
    Xie KC,Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DANN synthesis after treatment of human lymphoblastoid cells with 2-chloro-(2-deoxy-fluoro-β-D-arabinofuranosyl) adenine. Cancer Res 1996; 56: 30303037.
  • 2
    Jeha S,Gaynon PS,Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukaemia. J Clin Oncol 2006; 24: 19171923.
  • 3
    Burnett AK,Russell N,Kell JW, et al. A phase II evaluation of single agent clofarabine as first line treatment for older patients with AML who are not considered fit for intensive chemotherapy. Blood 2004; 104( suppl 1): 248a. Abstract 869.
  • 4
    Faderl S,Gandhi V,O'Brien S, et al. Results of a phase I-II study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005; 105: 940947.
  • 5
    Karp JE,Ricklis RM,Balakrishnan K, et al. A phase I clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 2007; 110: 17621769.
  • 6
    Chang JE,Medlin SC,Kahl BS, et al. Augmented and standard Berlin- Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia. 2008; 49: 22982307.
  • 7
    Preti HA,Huh YO,O'Brien SM, et al. Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis. Cancer 1995; 76: 15641570.
  • 8
    Vitale A,Guarini A,Ariola C, et al. Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial. Hematologica 2007; 92: 342348.
  • 9
    Lucio P,Gaipa G,van Lochem EG, et al. BIOMED-I concerted action report: Flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted action investigation of minimal residual disease in acute leukemia: International standardization and clinical evaluation. Leukemia. 2001; 15: 11851192.
  • 10
    Linenberger ML,Hong T,Flowers D, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 2001; 98: 988994.